AEs With BTKis

CE / CME

Multidisciplinary Perspectives on CLL-Related Symptoms and Managing Adverse Events With BTK Inhibitors

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Nurses: 0.75 Nursing contact hour

Released: May 31, 2022

Expiration: May 30, 2023

Nichole Fisher
Nichole Fisher, RN, BSN
Nicole Lamanna
Nicole Lamanna, MD
Anthony J. Perissinotti
Anthony J. Perissinotti, PharmD, BCOP

Activity

Progress
1
Course Completed

References

  1. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745-2760.
  2. Ibrutinib prescribing information. Sunnyvale, CA: Pharmacyclics, LLC; 2020.
  3. Acalabrutinib prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.
  4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: chronic lymphocytic leukemia/small lymphocytic lymphoma. v.2.2022. nccn.org. Accessed May 13, 2022.
  5. Zanubrutinib prescribing information. San Mateo, CA: BeiGene USA, Inc.; 2021.
  6. Tam CS, Giannopoulos K, Jurczak W, et al. SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Presented at: 2021 American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 396.
  7. Hillmen P, Eichhorst B, Brown JR, et al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Presented at: 2021 European Hematology Association Congress; June 9-17, 2021. Abstract LB1900.
  8. Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020;2020:336-345.
  9. Byrd JC, Hillmen P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7500.
  10. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892-901.
  11. Mato AR, Pagel JM, Coombs CC, et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study. Presented at: 2021 American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 391.
  12. O’Brien S, Hillmen P, Coutre S, et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18:648-657.e15.
  13. Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58:1630-1639.
  14. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432-443.
  15. Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129:2612-2615.
  16. Rhodes J, Barr PM, Ujjani CS, et al. The impact of frontline ibrutinib dose reduction and interruption on outcomes in chronic lymphocytic leukemia (CLL) patients. Blood. 2017;130(suppl 1):4313.